

LISTING OF THE CLAIMS

1-21. (Canceled)

22. (Currently Amended) A chimeric receptor protein comprising:

(a) an extracellular portion comprising

(i) a CD4 portion that specifically recognizes and binds to gp120 on HIV infected cells, and

(ii) a projection portion that projects the CD4 domain portion at least 48 angstroms away from the cell membrane of a cell bearing said receptor;

wherein said extracellular portion does not mediate HIV infection;

(b) a transmembrane portion; and

(c) an intracellular portion that signals a cell bearing said receptor to destroy a receptor-bound HIV-infected cell.

23. (Previously Presented) The receptor of claim 22, wherein said CD4 portion consists of amino acids 1-394 of SEQ ID NO: 29.

24. (Previously Presented) The receptor of claim 22, wherein said CD4 portion consists of amino acids 1-200 of SEQ ID NO: 31.

25. (Previously Presented) The receptor of claim 22, wherein said transmembrane portion comprises the CD7 transmembrane domain of SEQ ID NO: 35.

26. (Previously Presented) The receptor of claim 22, wherein said extracellular portion further comprises the IgG1 hinge, CH2, and CH3 domains of SEQ ID NO: 33.

27. (Canceled)

28. (Currently Amended) The receptor of claim 22, wherein said projection portion projects the CD4 domain portion at least 72 angstroms away from the cell membrane of a cell bearing said receptor.

29. (Previously Presented) The receptor of claim 22, wherein said intracellular portion is the signal-transducing portion of a T cell receptor protein, a B cell receptor protein, or an Fc receptor protein.

30. (Previously Presented) The receptor of claim 29, wherein said T cell receptor protein is  $\zeta$ .

REMARKS

The specification has been amended to delete the priority claim to U.S. Patent Application Nos. 07/847,566 and 07/665,961, filed March 6, 1992 and March 7, 1991, respectively.

In addition, claims 22 and 28 have been amended to conform their language with that of their respective dependent claims. No new matter has been added by the present amendments.

In response to the obviousness-type double patenting rejection over claims 13-14 of U.S. Patent No. 6,753,162 as set forth in the March 22, 2005 Office Action, Applicants concurrently submit a Terminal Disclaimer in which Applicants disclaim the terminal portion of the term of the entire patent to be granted upon the present application subsequent to the expiration date of U.S. Patent No. 6,753,162.

FEB. 7. 2006 5:13PM CLARK & ELBING

NO. 223 P. 7/10


CONCLUSION

Applicants submit that the application is now in condition for allowance, and this action is hereby respectfully requested.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 07 February 2006

  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045